journal of men's health
Volume 5, Issue 3 , Pages 234-238 , September 2008

Androgen replacement therapy in patients with age-related hypogonadism after radical retropubic prostatectomy for localized prostate cancer

  • D.Y. Pushkar, MD, PhD

      Affiliations

    • Moscow State Medical University, Department of Urology, Moscow, Russia
    • ,
  • A.V. Govorov, MD, PhD

      Affiliations

    • Semashko State Medical Dental University of Moscow, Moscow, Russia
    • Corresponding Author InformationCorresponding author.
    • ,
  • A.S. Segal, MD, PhD

      Affiliations

    • Moscow State Medical University, Department of Urology, Moscow, Russia

Received 15 January 2008 ,Accepted 1 April 2008.

References 

  1. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–523
  2. Slater S, Oliver RT. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging. 2000;17:431–439
  3. McConnell J, Denis L, Akaza H, Khoury S, Schalken J, editors. Chapter 9: Androgen therapy in men at risk for prostate disease. In: McConnell J, Denis L, Akaza H, Khoury S, Schalken J, editors. Prostate Cancer. Paris: Health Publications; 2006. pp. 360–2.
  4. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172:920–922
  5. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533–536
  6. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482–492
  7. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006;50:935–939
  8. Pushkar DY, Segal AS. Androgenozamestitel’naya terapiya i sostoyanie predstatel’noi zhelezy [Androgen replacement therapy and the condition of the prostate]. Farmateka. 2006;15:55–62[In Russian]
  9. Tubaro A. Testosterone and prostate cancer. Eur Urol. 2007;51:293–295
  10. Rhoden E, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk of prostate cancer: results of 1 year treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170:2348–2351
  11. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol. 2000;163:824–827
  12. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169:1670–1675

PII: S1875-6867(08)00147-4

doi: 10.1016/j.jomh.2008.04.007

journal of men's health
Volume 5, Issue 3 , Pages 234-238 , September 2008

Article Tools